SL VaxiGen Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SL VaxiGen Inc. - overview
Established
2017
Location
Seongnam, -, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam, South Korea, and founded in 2017, SL VaxiGen Inc. operates as a research and development company dedicated to developing innovative vaccine therapeutics based on complementary platforms. The CEO of the company is the Post-doc fellowship, Harvard Medical School. Before worked in this company, the CFO, Kyeong Ha Lee was the director of Finance Div.
, Genexine. Inc. The company possesses two technologies which are DNA vaccine technology and B. S.
A platform technology. The DNA vaccine technology is a highly efficient vector the company combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in efficient expression vector system. The targeting to vaccine-induced CTLs of the company, enable the vaccine-induced CTL (cytotoxic T lymphocyte) to be increased in the course of immune responses. The pipelines of the company include SL-V10, SL-V20, SL-V30, which can be used in infectious diseases and SL-V60 used to cure cancer.
Current Investors
AJU IB Investment, Yuanta Securities Korea, Meritz Securities
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT, Therapeutic Devices
Website
www.slvaxigen.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
SL VaxiGen Inc. - timeline of key events
SL VaxiGen Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|
| Revenue (USD) | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (5,633,853,533) | - | - | - |
| Operating Income (USD) | (5,638,186,533) | - | - | - |
| Operating Margin | - | - | - | - |
| % EBITDA Margin | - | - | - | - |
| NET Income (USD) | (11,482,420,246) | - | - | - |
| % Net Margin | - | - | - | - |
SL VaxiGen Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.